Please try another search
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Peter Thelin | 66 | 2011 | Independent Director |
Uli Hacksell | 72 | 2019 | Independent Director |
Aleksandar Danilovski | 48 | 2020 | Independent Director |
Michael Shalmi | 57 | 2019 | Independent Chairman of the Board |
Axel Gaston Glasmacher | 63 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review